Author: Jrhau Lung; Yu-Shih Lin; Yao-Hsu Yang; Yu-Lun Chou; Geng-He Chang; Ming-Shao Tsai; Cheng-Ming Hsu; Reming-Albert Yeh; Li-Hsin Shu; Yu-Ching Cheng; Hung Te Liu; Ching-Yuan Wu
Title: The potential SARS-CoV-2 entry inhibitor Document date: 2020_3_26
ID: 7w79zeib_5
Snippet: In addition, Phe486 of RBD forms van der Waals forces with Met82 of . CC-BY 4.0 International license author/funder. It is made available under a The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.26.009803 doi: bioRxiv preprint 6 ACE24 (Fig 1) (5) . However, the sequence identity of the spike protein between SARS-CoV-2 and SARS-CoV is 76%, and major variation exists at the N-terminus enc.....
Document: In addition, Phe486 of RBD forms van der Waals forces with Met82 of . CC-BY 4.0 International license author/funder. It is made available under a The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.26.009803 doi: bioRxiv preprint 6 ACE24 (Fig 1) (5) . However, the sequence identity of the spike protein between SARS-CoV-2 and SARS-CoV is 76%, and major variation exists at the N-terminus encoding the RBD(7). Since RBD of spike protein is surface-exposed and promotes entry into host cells, it could be a potential target for therapy and vaccination using small molecules and neutralizing antibodies to treat COVID-19 (4, 8) .
Search related documents:
Co phrase search for related documents- host cell and potential target: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- host cell and SARS CoV SARS spike protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- host cell and sequence identity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- host cell and small molecule: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- host cell and spike protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- host cell and vaccination therapy: 1, 2, 3
- host cell entry and potential target: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- host cell entry and SARS CoV SARS spike protein: 1, 2, 3, 4, 5, 6, 7, 8, 9
- host cell entry and sequence identity: 1, 2, 3, 4
- host cell entry and small molecule: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- host cell entry and spike protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- major variation and spike protein: 1, 2, 3, 4
- potential target and SARS CoV SARS spike protein: 1, 2, 3, 4
- potential target and sequence identity: 1, 2, 3, 4, 5
- potential target and small molecule: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- potential target and spike protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- potential target and vaccination therapy: 1
- SARS CoV SARS spike protein and small molecule: 1, 2
- SARS CoV SARS spike protein and spike protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
Co phrase search for related documents, hyperlinks ordered by date